EURORDIS Proposal on the Revision of the Orphan Medicinal Products and Paediatric Regulation
In the context of the revision, at this end of 2022, of the 1999 European Regulation on Orphan Medicinal Products, and of the 2004 European Regulation on Paediatric Medecines, EURORDIS has published their proposal on how to improve the availabilty and accessibility of medicinal products for rare diseases.
In the proposal, EURORDIS provides concrete points of action that could help create a more robust regulatory framework that will drive innovation and improve access to transformative treatments for those living with a rare disease the years to come, with hope that European decision makes take the opportunity of this regulatory revision to make necessary changes to legislation.
- To read more about “More information on the revision process”
